课题基金 / 基金详情

Discovery of New Tuberculosis Drug Leads Targeting Cell Wall Biosynthesis

Discovery of New Tuberculosis Drug Leads Targeting Cell Wall Biosynthesis
发现针对细胞壁生物合成的新结核病药物先导物
批准号:
nhmrc : 1082533
负责人:
Dr Nicholas West
金额:
$47.66万
依托单位国家:
澳大利亚
项目类别:
Project Grants
财政年份:
2015
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2015-01-01 至 2017-12-31

项目摘要

项目成果

Dr Nicholas West的其他基金

相似基金

相关文献

中文摘要
翻译
由于结核病的病原体结核分枝杆菌对目前的治疗方法具有广泛的耐药性,因此迫切需要开发治疗结核病的新疗法。该研究项目的总体目标是通过开发细菌衍生的天然产物的结构类似物,即抑制结核分枝杆菌细胞壁合成的三霉素,来确定新的结核病药物先导物。
英文摘要
There is a desperate need for the development of new therapies for the treatment of TB due to widespread resistance of Mycobacterium tuberculosis, the causative agent of TB, to current therapies. The overall goal of this research project is to identify new TB drug leads through the development of structural analogues of bacterially-derived natural products called the sansanmycins that inhibit cell wall synthesis in Mycobacterium tuberculosis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Killing infected cells as a mechanism to eradicate tuberculosis
Preventing the evolution of transmissible nitroimidazole resistance in Mycobacterium tuberculosis
  • 批准号:
    nhmrc : 1139832
  • 项目类别:
    Project Grants
  • 资助金额:
    $44.93万
  • 财政年份:
    2018
  • 负责人:
    Dr Nicholas West
  • 依托单位:
Killing infected cells as a mechanism to eradicate tuberculosis
  • 批准号:
    nhmrc : GNT1147010
  • 项目类别:
    Project Grants
  • 资助金额:
    $107.08万
  • 财政年份:
    2018
  • 负责人:
    Dr Nicholas West
  • 依托单位:
Discovery of New Tuberculosis Drug Leads Targeting Cell Wall Biosynthesis
  • 批准号:
    nhmrc : GNT1082533
  • 项目类别:
    Project Grants
  • 资助金额:
    $46.16万
  • 财政年份:
    2015
  • 负责人:
    Dr Nicholas West
  • 依托单位:
海外基金